Extended Data Fig. 8: ZR-75-1 xenograft sequencing data representing tumors harvested 5 days post-AR agonist treatment in vivo.

a, Read density plots (upper panel) and heatmaps (lower panel) of ER ChIP-seq data from ZR-75-1 xenograft tumors, illustrating the loss of ER binding upon activation of AR by agonists (SARM, DHT). Data is presented as an average of 4 (E2 + Veh) or 5 (E2 + SARM, E2 + DHT) replicate tumors. b, Two-factor log-ratio (M) plot showing SARM-induced changes in ER and AR enrichment at consensus ER (yellow-orange), AR (blue), or Shared (that is AR and ER co-occupied; grey-brown; plotted at rear) binding sites seen across the Vehicle, SARM, and DHT treatment arms. Example binding sites near ER target genes and AR target genes are highlighted in pink and purple, respectively. Enrichment scores were calculated from an average of 4 (ER, E2) or 5 (ER, E2 + SARM, AR E2, E2 + SARM) tumors. c, Read density plots (upper panel) and heatmap (lower panels) depictions of ER ChIP-seq presented in (a,b). d, Genome browser images of ER and AR binding in ZR-75-1 xenograft tumors treated with E2 or E2 + SARM at loci associated with ER target genes (MYB, CCND1; left panels) and AR target genes (SEC14L2, ZBTB16; right panels). Data represents an average of 4-5 replicates as described in (b). e, Normalized enrichment scores for signature gene sets correlated with E2 or E2 + SARM treatments, derived using RNA-seq data associated with Extended Data Fig. 7e.